Protecting UK adolescents and adults against meningococcal serogroup B disease

References

• Vyse A, Anonychuk A, Jäkel A, et al. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11:597–604.
   PubMed Web of Science ®Google Scholar
• Pelton S. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolescent Health. 2016;59:S3–S11.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcón P, Carlos J, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–328.
   PubMed Web of Science ®Google Scholar
• Poolman J, Richmond P. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness. Expert Rev Vaccines. 2015;14:1277–1287.
   PubMed Web of Science ®Google Scholar
• Oviedo-Orta E, Ahmed S, Rappuoli R, et al. Prevention and control of meningococcal outbreaks: the emerging role of serogroup B meningococcal vaccines. Vaccine. 2015;33:3268–3635.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Pizza M, Masignani V, et al. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines. 2017;16(5):433–51.
   PubMed Web of Science ®Google Scholar
• Harrison L. Vaccines for prevention of group B meningococcal disease: not your father’s vaccines. Vaccine. 2015;33:D32–D38.
   PubMed Web of Science ®Google Scholar
• Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine. 2013;31:2638–2646.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter C, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. Bmj. 2014;349:g5725.
   PubMed Web of Science ®Google Scholar
• Christensen H, Trotter C. Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England. Vaccine. 2017;35:208–211.
   PubMed Web of Science ®Google Scholar
• Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15:641–658.
   PubMed Web of Science ®Google Scholar
• Public Health England. [Cited 2017 Aug 7]. Available from: https://www.gov.uk/government/organisations/public-health-england.
   Google Scholar
• ECDC. Surveillance of invasive bacterial diseases in Europe. 2015. [cited 2017 Aug 7] available at https://ecdc.europa.eu/en.
   Google Scholar
• Edge C, Waight P, Ribeiro S, et al. Clinical diagnoses and outcomes of 4619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: linkage analysis of multiple national databases. J Infect. 2016;73:427–436.
   PubMed Web of Science ®Google Scholar
• Sridhar S, Greenwood B, Head C, et al. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15:1334–1346.
   PubMed Web of Science ®Google Scholar
• Viner R, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774–783.
   PubMed Web of Science ®Google Scholar
• Kennedy I, Hoek A, Ribeiro S, et al. Short-term changes in the health state of children with group B meningococcal disease: a prospective, national cohort study. PLoS ONE. 2017;12:e0177082.
   PubMed Web of Science ®Google Scholar
• Le Ngoc Tho S, Ader F, Ferry T, et al. Vaccination against serogroup B Neisseria meningitidis: perceptions and attitudes of parents. Vaccine. 2015;33:3463–3470.
   PubMed Web of Science ®Google Scholar
• Gianchecci E, Torelli A, Piccini G, et al. Neisseria meningitidis infection: who, when and where? Expert Rev Anti Infect Ther. 2015;13(10):1249–1263.
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Lekshmi A, Parikh S, et al. Frequent capsule switching in ‘ultra-virulent’ meningococci – are we ready for a serogroup B ST-11 complex outbreak? J Infect. 2017;75:95–103.
   PubMed Web of Science ®Google Scholar
• Kriz P, Wieffer H, Holl K, et al. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. Expert Rev Vaccines. 2011;10:1477–1486.
   PubMed Web of Science ®Google Scholar
• Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017;35:2034–2041.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Flood J, Ramsay M, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30:3710–3716.
   PubMed Web of Science ®Google Scholar
• Public Health England. Invasive meningococcal B infections laboratory reports in England by capsular group and epidemiological year, 1998/99–2015/16 [cited 2017 Aug 7]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/563521/Table_1_Invasive_meningococcal_infections_lab_reports__England_by_capsular_group___epi_year.pdf.
   Google Scholar
• Parikh S, Andrews N, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388:2775–2782.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Ramsay M, Borrow R, et al. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101:91–95.
   PubMed Web of Science ®Google Scholar
• Public Health England. Invasive meningococcal B infections laboratory reports in England by age group and epidemiological year, 1998/99–2016/17 [cited 2018 Jan 11]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/563526/Table_4_Invasive_meningococcal_B_infections_lab_reports__England_by_age_group___epi_year.pdf.
   Google Scholar
• Trotter C, Gay N, Edmunds W, et al. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134:556–566.
   PubMed Web of Science ®Google Scholar
• Trotter C, Maiden M. Carriage and transmission of Neisseria meningitidis. Expert Rev Vaccines. 2009;8:851–861.
   PubMed Web of Science ®Google Scholar
• Hogea C, Van Effelterre T, Vyse A. Exploring the population-level impact of MenB vaccination via modeling: potential for serogroup replacement. Human Vacc & Immunother. 2016;12:451–466.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–861.
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarro M, Wolter J, Hogea C, et al. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther. 2011;9:761–774.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12:950–957.
   PubMed Web of Science ®Google Scholar
• Jeppesen C, Snape M, Robinson H, et al. Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. J Infect. 2015;71:43–52.
   PubMed Web of Science ®Google Scholar
• Neal K, Nguyen-Van-Tam J, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ. 2000;320:846–849.
   PubMed Web of Science ®Google Scholar
• Ala’Aldeen D, Neal K, Ait-Tahar K, et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J Clin Micro. 2000;38:2311–2316.
   PubMed Web of Science ®Google Scholar
• Oldfield N, Cayrou C, Al-Jannat A, et al. Rise in group W meningococcal carriage in university students, United Kingdom. Emerg Infect Dis. 2017;23:1009–1011.
   PubMed Web of Science ®Google Scholar
• Cleary P, Calvert N, Gee S, et al. Variations in Neisseria meningitidis carriage by socioeconomic status: a cross-sectional study. Journal of Public Health. 2015;38:61–70.
   PubMed Web of Science ®Google Scholar
• Trotter C, McVernon J, Ramsay M, et al. Optimising the use of conjugate vaccines to prevent disease caused by haemophilus influenzae type B, Neisseria meningitidis and Streptococcus Pneumoniae. Vaccine. 2008;26:4434–4445.
   PubMed Web of Science ®Google Scholar
• Delbos V, Lemée L, Bénichou J, et al. Meningococcal carriage during a clonal meningococcal B outbreak in France. Eur J Clin Microbiol Infect Dis. 2013;32:1452–1459.
   Web of Science ®Google Scholar
• Nolan T, O’Ryan M, Wassil J, et al. Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine. 2015;33:4437–4445.
   PubMed Web of Science ®Google Scholar
• Anonychuk A, Woo G, Vyse A, et al. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review. Pharmacoeconomics. 2013;31:563–576.
   PubMed Web of Science ®Google Scholar
• Brooks R, Woods C, Benjamin D, et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. Clin Infect Dis. 2006;43:49–54.
   PubMed Web of Science ®Google Scholar
• Rouaud P, Perrocheau A, Taha M, et al. Prolonged out break of B meningococcal disease in the Seine-Maritime Department, France, January 2003 to June 2005. Eurosurveillance. 2006;11:178–181.
   Google Scholar
• Caron F, Parent du Châtelet I, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal b vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455–463.
   PubMed Web of Science ®Google Scholar
• Whelan J, Bambini S, Biolchi A, et al. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives. Expert Rev Vaccines. 2015;14:713–736.
   PubMed Web of Science ®Google Scholar
• Sevestre J, Hong E, Delbos V, et al. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: lessons of the Normandy campaign. Vaccine. 2017;35:4029–4033.
   PubMed Web of Science ®Google Scholar
• Chatt C, Gajraj R, Hawker J, et al. Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013. Euro Surveill. 2014;19(44):pii=20949.
   PubMedGoogle Scholar
• Harrison L, Dwyer D, Maples C, et al. Risk of meningococcal infection in college students. JAMA. 1999;281:1906–1910.
   PubMed Web of Science ®Google Scholar
• Neal K, Nguyen-Van-Tam J, Monk P, et al. Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation. Epidemiol Infect. 1999;122:351–357.
   PubMed Web of Science ®Google Scholar
• Nelson S, Charlett A, Orr J, et al. Risk factors for meningococcal disease in university halls of residence. Epidemiol Infect. 2001;126:211–217.
   PubMed Web of Science ®Google Scholar
• Tully J, Viner R, Coen P, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332:445–450.
   PubMed Web of Science ®Google Scholar
• Mandal S, Campbell H, Ribeiro S, et al. Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine. Vaccine. 2017;35:5814–5818.
   PubMed Web of Science ®Google Scholar
• Atkinson B, Gandhi A, Balmer P, et al. History of meningococcal outbreaks in the United States: implications for vaccination and disease prevention. Pharmacotherapy. 2016;36:880–892.
   PubMed Web of Science ®Google Scholar
• Mandal S, Wu H, MacNeil J, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344–348.
   PubMed Web of Science ®Google Scholar
• MacNeil J, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR. 2015;64(41):1171–1179 [cited 2017 Aug 7]. www.cdc.gov/mmwr.
   PubMed Web of Science ®Google Scholar
• AAP Committee on Infectious Diseases. Recommendations for serogroup B meningococcal vaccine for persons 10 years and older. Pediatrics. 2016;138(3):e20161890.
   PubMed Web of Science ®Google Scholar
• Khalil M, Borrow R. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario. Travel Med Infect Dis. 2009;7:231–234.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis. 2012;16:e574–582.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Barkham T, Earnest A, et al. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ. 2002;325:365–366.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Celik M, Demir E, et al. Acquisition of meningococcal serogroup W-135 carriage in Turkish Hajj Pilgrims who had received the quadrivalent meningococcal polysaccharide vaccine. Clin Vaccine Immunotherapy. 2013;20:66–68.
   PubMed Web of Science ®Google Scholar
• Memish Z, Al-Tawfiq J, Almasri M, et al. Neisseria meningitidis nasopharyngeal carriage during the Hajj: a cohort study evaluating the need for ciprofloxacin prophylaxis. Vaccine. 2017;35:2473–2478.
   PubMed Web of Science ®Google Scholar
• Yezli S, Wilder-Smith A, Bin Saeed A. Carriage of Neisseria meningitidis in the Hajj and Umrah mass gatherings. Int J Infect Dis. 2016;47:65–70.
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Scott K, Ure R, et al. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016;21(45):pii=30395.
   Google Scholar
• Smith-Palmer A, Oates K, Webster D, et al. Outbreak of Neisseria meningitidis capsular group W among scouts returning from the World Scout Jamboree, Japan, 2015. Euro Surveill. 2016;21(45):pii=30392.
   Google Scholar
• Simmons R, Kirwan P, Beebeejaun K, et al. Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Medicine. 2015;13:297.
   PubMed Web of Science ®Google Scholar
• Christie D, Rashid H, El-Bashir H, et al. Impact of meningitis on intelligence and development: a systematic review and meta-analysis. PLos One. 2017;12:8.
   Web of Science ®Google Scholar
• Immunisation of individuals with underlying medical conditions [cited 2018 Jan 11]. www.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf .
   Google Scholar
• Folaranmi T, Kretz C, Kamiya H, et al. Increased risk for meningococcal disease among men who have sex with men in the United States, 2012–2015. Clin Infect Dis. 2017;65(5):756–763.
   PubMed Web of Science ®Google Scholar
• Le Ngoc Tho S, Ader F, Ferry T, et al. Vaccination against serogroup B Neisseria meningitidis: perceptions and attitudes of parents. Vaccine. 2015;33:3463–3470.
   PubMed Web of Science ®Google Scholar
• Bland M, Clear G, Grogan A, et al. Mum’s the word: factors that influenced young adults’ participation in the New Zealand meningococcal B immunisation programme. N Z Med J. 2009;11:30–38.
   Google Scholar
• Dubé E, Gagnon D, Hamel D, et al. Parents’ and adolescents’ willingness to be vaccinated against serogroup B meningococcal disease during a mass vaccination in Saguenay–lac-St-Jean (Quebec). Can J Infect Dis Med Microbiol. 2015;26:163–167.
   PubMed Web of Science ®Google Scholar
• Stephens D. Boosters for meningococcal B vaccines? Lancet. 2017;17:4–6.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H. Commentary: impact of meningococcal group B OMV vaccines, beyond their brief. Hum Vaccin Immunother. 2017;1–6.
   PubMed Web of Science ®Google Scholar
• Whelan J, Kløvstad H, Haugen I, et al. Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway. Emerg Infect Dis. 2016;22(6):1137–1139.
   PubMed Web of Science ®Google Scholar